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Alzheimer’s disease (AD) is a major cause of dementia, disability, and death in the
elderly. Despite recent advances in our understanding of the basic biological mecha-
nisms underlying AD, we do not know how to prevent it, nor do we have an approved
disease-modifying intervention. Both are essential to slow or stop the growth in
dementia prevalence. While our current animal models of AD have provided novel
insights into AD disease mechanisms, thus far, they have not been successfully used
to predict the effectiveness of therapies that have moved into AD clinical trials. The
Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease
(MODEL-AD; www.model-ad.org) Consortium was established to maximize human
datasets to identify putative variants, genes, and biomarkers for AD; to generate, char-
acterize, and validate the next generation of mouse models of AD; and to develop a
preclinical testing pipeline. MODEL-AD is a collaboration among Indiana University
(IU); The Jackson Laboratory (JAX); University of Pittsburgh School of Medicine (Pitt);
Sage BioNetworks (Sage); and the University of California, Irvine (UCI) that will gener-
ate new AD modeling processes and pipelines, data resources, research results, stan-
dardized protocols, and models that will be shared through JAX’s and Sage’s proven
dissemination pipelines with the National Institute on Aging–supported AD Centers,
academic and medical research centers, research institutions, and the pharmaceutical
industry worldwide.
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1 INTRODUCTION
Evidence suggests that Alzheimer’s disease (AD), the most common
dementing disorder of late life, is the third leading cause of death in
the United States.1 An estimated 5.8 million Americans currently have
AD and approximately 700,000 individuals over the age of 65 will
die with AD in 2019, with another 18.5 million individuals acting as
unpaid caregivers for those afflicted by the disease.2 Tragically, the
progression of the disease is lengthy and there is currently no effective
treatment.
The AD brain exhibits unique pathological alterations, including fil-
amentous inclusions of the microtubule-associated protein tau in neu-
ronal cell bodies and processes; extracellular deposits of amyloid beta
(Aβ) in senile plaques and within the walls of leptomeningeal/cerebral
vessels; marked neuroinflammation and activation of innate immune
cells; and synaptic and neuronal cell loss. Alois Alzheimer identified
plaques and tangles in a patient with presenile dementia in 1906, but
despite decades of research, the precise relationship among plaques,
tangles, and dementia remains unknown. Clues to understanding the
biological pathwaysunderlying thesepathological processes havebeen
provided by genetic studies of human AD.
AD is generally classified as early-onset (EOAD) or late-onset
(LOAD), based on factors including age of onset and genetic markers.
The majority of cases of EOAD are caused by mutations in the amy-
loid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes,
but EOAD accounts for only a small fraction of the total AD cases.
Unlike EOAD, genetic susceptibility to LOAD is more complex with
variations in many genes significantly associated with increased risk
of varying degree. The greatest genetic risk factor for LOAD in the
human population is the ε4 allele of apolipoprotein E (APOE), which
accounts for ≈30% of risk. More recently, next generation sequencing
determined that the R47H variation in triggering receptor expressed
onmyeloid cells 2 (TREM2) also conferred increased risk for AD.3 With
an increased odds ratio for carriers second only to APOEε4 carriers,
TREM2R47H is the second greatest known genetic risk factor for LOAD.
To date, more than 20 other genetic loci have been associated with
LOAD by genome-wide association studies (GWAS), albeit these indi-
vidually confer a small increase in risk (between1%and3%). Candidate
genes in these loci fall into a variety of pathways including cholesterol
trafficking, inflammation, and endosomal recycling suggesting that AD
is caused by perturbations in multiple biological processes. However,
the mechanisms by which individual or combinations of genetic risk
variants contribute to AD risk, onset, and progression are not known.
This knowledge gap is severely hampering the development of treat-
ments for LOAD.
Based uponEOADstudies,multiple approaches towardAβ-directed
therapies have been developed and tested in clinical trials, including
active and passive Aβ immunization,4 γ- and β-secretase inhibitors, γ-
secretase modulators,5 and Aβ aggregation inhibitors. Notably, these
strategies have thus far failed in AD clinical trials, although some of
these trials are continuing and showing some promise.6 There are
numerous potential explanations as to why these clinical trials have
failed, including stage of disease targeted, mechanism of delivery, suit-
ability of the patient population, effective engagement of target and
off-target effects, suitability of the target, face and construct validity
of the animalmodels, andothers.7,8 However, the exact reasons for fail-
uresof the clinical trials remain tobeestablished.A recommendationof
the National Institute on Aging (NIA) Alzheimer’s Research Summit in
2015 was to develop and characterize novel animal models of AD that
would facilitate the development of novel AD therapies, using genetics
and systems biology to inform animal model development and subse-
quent pre-clinical drug testing.
Over the past two decades, multiple groups, including our own,
have focused on developing and characterizing genetically engineered
rodent models of EOAD. These models have provided key insights
into genes implicated in human AD and how they lead to some neu-
ropathological abnormalities observed in AD with a focus on Aβ and
tau.9 While current models have provided critical information on bio-
logical mechanisms underlying Aβ and tau pathology, there have been
a number of confounds that have limited their utility, particularly for
preclinical studies assessing potential AD therapies.7 First, existing
animal models have focused on EOAD, although it remains unclear
whether the relatively uncommon EOAD cases and the more com-
mon LOAD cases proceed through identical disease mechanisms. Sec-
ond, most mouse models of Aβ pathology do not exhibit extensive
neurodegeneration.10,11 Exceptions include the 5xFAD mouse model
of Aβ pathology, which exhibits regional-specific neurodegeneration
and the hTau mouse model of tau pathology.13–15 Third, to date, no
single EOAD model exhibits both Aβ and tau pathology, although the
3xTgmousemodel, which in addition to EOADmutations also contains
a mutation in tau associated with frontotemporal dementia, devel-
ops both plaques and hyperphosphorylated tau (Oddo et al., 2003).16
Fourth, most existing models significantly and ectopically overexpress
the relevant transgenes to observe AD pathologies within a mouse’s
lifespan, which may introduce non-physiologic effects which do not
reflect human disease progression. Fifth, although many mouse mod-
els of Aβ and tau pathology exhibit age-related behavioral abnormal-
ities, it has proven difficult to relate these deficits to specific impair-
ments observed in human AD.8 Sixth, manymodels were generated on
hybrid genetic backgrounds and could not be maintained in uniform
genetic backgrounds due to premature lethality and seizures observed
in many models,17–22 making them difficult to use for preclinical stud-
ies. Seventh, the use of many models has been restricted due to legal
constraints.23 Eighth, most studies have not examined the various ani-
mal models in a side-by-side manner to directly assess reproducibil-
ity. Ninth, few mouse models of AD have been carefully examined for
age-related alterations in biomarkers and brain imaging abnormalities
across the lifespan to relate to those observed in human AD.8 Finally,
preclinical therapeutic testing conducted in current models and with
traditional behavioral tests have failed to predict clinical efficacy for
cognitive improvement in human clinical trials; however, the mouse
models predicted Aβ lowering without improvements in cognition.7
Therefore, a critical need exists to generatemultiple newmodels ofAD,
particularly LOAD, given that recent genetic and systems biology stud-
ies of LOAD suggest that different pathwaysmay contribute to disease
pathogenesis from those observed in EOAD.
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F IGURE 1 Workflow for creating and testing novel animal models
of late-onset Alzheimer’s disease
To meet this essential need, Model Organism Development
and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD;
www.model-ad.org) was established by the NIA to (1) identify novel
combinations of genetic variants that increase risk for LOAD, (2)
develop new animal models for LOAD including humanized Aβ and
tau models that recapitulate key hallmarks of the human disease, and
(3) develop robust preclinical testing pipelines, and identify and test
novel therapeutic agents (Figure 1). Despite failures in most of the
clinical trials for AD, key recent advances provide renewed optimism
that treatments for AD will be developed. First, dedication of new
funds for research and development targeting AD specifically has
enabled the establishment and coordination of multi-institutional and
inter-disciplinary precompetitive consortia to identify, characterize,
and deliver new therapies to the clinic by 2025. In addition to the
Alzheimer’s Disease Research Centers (ADRCs) that are provid-
ing patient samples and clinical data, other key consortia include
MODEL-AD, the Accelerating Medicines Partnerships–Alzheimer’s
Disease (AMP-AD), the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), the Alzheimer’s Disease Sequencing Project (ADSP), the
MolecularMechanisms of theVascular Etiology of Alzheimer’s Disease
(M2OVE-AD), and the Target Enablement to Accelerate Therapy
Development for Alzheimer’s Disease (TREAT-AD) Consortium. Many
of these consortia are focused on accelerating the process to identify
novel therapeutic targets, moving these targets forward, testing in
preclinical models, and ultimately to delivering therapies to human
AD patients (Figure 2). Second, many groups, including our own, are
developing novel computational approaches to interrogate large-scale
datasets to understand complex genetic disorders including AD.
Third, recent advances in manipulating genomes, particularly the
development of gene editing by clustered regularly interspaced short
palindromic repeats (CRISPR) has accelerated and reduced the cost of
introducing human relevant variants in model organisms. Last, imaging
technologies in both humans and model organisms allow for more
accurate assessment of particularly early stages of AD.
2 THE OVERARCHING PRINCIPLES OF
MODEL-AD
Themajor aims ofMODEL-ADare to design, develop, characterize, and
distribute models for LOAD, and establish robust preclinical pipelines
for testing new therapies. Our strategy will be to generate new rodent
models, initially in the mouse. Mice will be engineered using CRISPR
andother traditionalmethods to carry combinations of humanvariants
identified using computational analyses of human datasets made avail-
able from AMP-AD, M2OVE-AD, ADSP, ADNI, and other sources. New
models will be “staged’’ to precisely define phenotypes and the rele-
vance tohumanAD.Human relevant-outcomemeasures particularly in
vivo imaging, blood biomarkers, and transcriptional profiling, as well as
traditional phenotyping methods including neuropathology, biochem-
istry, electrophysiology, and behavioral assays. Importantly, all models
and data will be made available for distribution. MODEL-AD will per-
mit these mice to be distributed without imposing any additional legal
or licensing restrictions on thesemodels or the use of data generated.
MODEL-AD is a collaboration among Indiana University (IU);
University of California, Irvine (UCI); The Jackson Laboratory (JAX);
University of Pittsburgh (Pitt); and Sage Bionetworks. Each institute
providesunique strengths that includeaproven track recordof transla-
tional neuroscience research and the 26-year-old Indiana Alzheimer’s
Disease Center at IU; 35-year-old UCI Alzheimer’s Disease Research
Center; 35-year-old University of Pittsburgh Alzheimer’s Disease
Research Center; more than eight decades of model production, phe-
notyping, and distribution (JAX); and a mission of open data curation
and dissemination (Sage). An administrative core, steering commit-
tee, and external advisory board ensure the aims and milestones of
MODEL-AD are met. To maximize uptake of all resources created by
MODEL-AD (mice, data, protocols, etc) all data will be made available
via the AD Knowledge Portal hosted on the Sage Synapse platform
(https://adknowledgeportal.synapse.org/), thereby expanding on an
established data resource for the AD research community. All mice
will be made available through the JAX AD Mouse Model Resource
(www.jax.org/ad-repository).
3 PRODUCTION, VALIDATION, AND
DISSEMINATION OF NEW MODELS FOR LOAD
A primary goal of MODEL-AD is to produce novel models for LOAD,
and extensively characterize them using human-relevant and trans-
latable outcome measures. New models will be assessed side-by-side
with prominent existing models (eg, 5xFAD, APP/PS1, 3xTg-AD, and
hTau). Wherever possible, models will be based on human-relevant
genetic variants. Models with “humanized” alleles of loci including APP
and MAPT (TAU), generated via genome engineering, will be used as a
platform to introduce additional risk alleles. For example, theMODEL-
AD consortium have already generated humanized Aβ models, which
express human non-mutated Aβ in the fully natural context of the
endogenous mouse APP gene. The resulting line, designated hAβ-KI
mouse model, produces human Aβ at physiological levels in all cell
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F IGURE 2 Role of theMODEL-AD center in the system of NIH-funded consortia created to discover new treatments for Alzheimer’s disease.
AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ADSP, Alzheimer’s Disease Sequencing Project; AMP-AD,
AcceleratingMedicines Partnerships–Alzheimer’s Disease; MODEL-AD,Model OrganismDevelopment and Evaluation for Late-onset Alzheimer’s
Disease; M2OVE-AD,MolecularMechanisms of the Vascular Etiology of Alzheimer’s Disease.
types that normally express APP, and it does so without the addition
of any FAD mutations or overexpression of APP or its metabolites.
Therefore, this innovative mouse overcomes many confounding vari-
ables affecting the traditional models of AD and may provide a much
more physiologically relevant understanding of the underlying mech-
anisms driving AD pathology by closely recapitulating the pathological
cascade of events that occurs in the majority of human AD patients.
Furthermore, this new model has also been engineered to permit the
conditional ablation of the humanized APP gene, by incorporating
LoxP sites flanking the Aβ sequence. By the virtue of these novel
features, the hAβ-KI mouse model can be used to address multiple
previously inaccessible questions surrounding the involvement of Aβ
in the pathogenesis of AD and multiple relevant genetic variants will
be incorporated into this new model. The hAβ-KI model was originally
characterized on a mixed C57BL/6J (B6J) and C57BL/6N (B6N)
genetic background but will also be available on B6J and B6N inbred
lines. The IU/Jax/PittMODEL-ADCenter has also created a humanized
Aβ knock-in model without the loxP sites, on a C57BL6J background.
The MODEL-AD consortium has also created an allelic series of
APOE variants (ε4, ε3, ε2; JAX IDs 27894, 29018, and 29017, respec-
tively) as well as mice carrying combinations of hAβ, APOE ε4, and
Trem2R47H on the B6J genetic background. Humanized MAPT alleles
will be incorporated as soon as possible. Female and male mice from
these platform strains are being characterized up to 24 months of
age using an extensive set of human-relevant assays. Additional AD-
relevant genetic variants and “humanized alleles’’ are being incorpo-
rated into the platform strains. Improved methods of in vitro fertil-
ization will be used to accelerate production of animal models with
different combinations of risk factors. MODEL-AD aims to generate
at least 50 new models for LOAD. Information on all available mod-
els can be found on the MODEL-AD website (https://www.model-ad.
org). Although models will be initially generated on the B6J back-
ground, there is a growing appreciation that alternative or even mul-
tiple genetic backgrounds will need to be considered to maximize the
relevance ofmousemodels to human LOAD (Onos et al., 2019; Neuner
et al., 2019).24,25 Work is under way within MODEL-AD to prioritize
themost appropriate genetic backgrounds.
A major limitation in generating new models has been the lack of
specific putative genetic variants in LOAD-relevant loci to precisely
engineer into the mouse genome. However, advances in genomics,
computation, and imaging are providing large data resources to
mine (eg, ADNI, AMP-AD, M2OVE-AD, ADSP, and the International
Genomics of Alzheimer’s Project). These datawill be leveraged to iden-
tify and prioritize candidate variants for animal models. Our initial
strategy is to use recent sequencing studies to aid in prioritizing vari-
ants in existing GWAS loci, including genes such as ABCA7, CR1, and
BIN1. Although the majority of GWAS loci have small effect sizes, our
hypothesis is that they will work in concert with other variants to
increase risk and should be assessed in a sensitized genetic context.
We then assess themouse genome for sequence and functional homol-
ogy to ensure the resulting model will faithfully reflect the genetics
of LOAD. Once existing loci have been assessed, we will incorporate
novel candidate genes and variants that may arise from the rapidly
expanding efforts to understand the genetics of AD. We expect that
these efforts will include modeling multiple non-coding variants and
integrating data fromexpression quantitative trait locus (eQTL) studies
and efforts to annotate the regulatory genome such as the ROADMAP
(Real-World Outcomes Across the Alzheimer’s Disease Spectrum for
Better Care: Multi-Modal Data Access Platform) and ENCODE (Ency-
clopedia of DNA Elements) projects for both mouse and human. The
expanding availability of quantitative traits related to AD pathology
from ADNI, eQTL, and other functional studies will enable greater
statistical power and phenotypic resolution. Importantly, such use of
advanced computational strategies will facilitate the ability to infer
epistatic and pleiotropic networks of genes that can aid in prioritizing
polygenic animal models.
Many of the new models will be initially characterized using a pri-
mary screening approach that prioritizes the most promising mod-
els for more extensive phenotyping using human-relevant outcome
measures. In some cases, the same strains will be characterized
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independently at multiple sites (eg, IU, JAX, and UCI) using standard-
ized protocols to ensure reproducibility of key AD-relevant pheno-
types. This extensive phenotyping will occur at multiple ages, up to
24 months of age, in male and female mice and, in addition to more
traditional phenotyping assays (eg, behavior, biochemistry, and neu-
ropathology), will include relevant in vivo positron emission tomog-
raphy (PET)/magnetic resonance (MR) imaging with autoradiography
validation of tracer compounds, blood and cerebrospinal fluid (CSF)
biomarkers, synaptic physiology analyses (eg, basal synaptic transmis-
sion, long-term potentiation, axon excitability, and transmitter release
kinetics), and molecular profiling by RNA sequencing. Genomic data
will be systematically compared to analogous human data from the
AMP-ADConsortium to identify the specific disease-related pathways
andmodulesmodified in each strain (Pandey et al., 2019; Johnson et al.,
2018; Logsdon et al., 2019).26-28 We have developed a new NanoS-
tring nCounter Mouse AD panel to specifically assess modifications of
LOAD-associated transcriptome modules that will be used in primary
screening of all newmouse strains.
Additional phenotyping for selected lines will also include pro-
teomics, metabolomics, and microbiome characterization. Assays are
designed to complement existing and forthcoming data from human
studies, and will systematically align the phenotypes of each mouse
modelwith correspondinghumandata. For example, early geneexpres-
sion signatures that appear in mouse models may be present in human
brain samples, providing evidence for pathway dysfunction in LOAD.
The identification of such signatures in human subpopulations may
further discriminate between heterogeneous etiologies within the
human population. These analyses will link precise genetic variation
in the mouse model with pathological outcomes that contribute to
LOAD, which can be further assessed in human carriers of the homol-
ogous variants. Staged mouse cohorts can potentially clarify tempo-
ral ordering of transcriptomic modifications that have accumulated
in human decedent cases. Such signals of disease progression will be
correlated with imaging and other molecular phenotypes to find can-
didate biomarkers for early disease. Furthermore, our analysis will
help refine key disease markers present in human data that may be
confounded by phenotypic variation unrelated to LOAD. Importantly,
these human/mouse comparisons will provide critical data to both
determine the most appropriate models to use in preclinical studies
and the novel targets to test as therapies for LOAD.
4 THE NEED FOR AN ACCESSIBLE VALIDATED
PRECLINICAL TESTING PIPELINE
Historically, preclinical screening of test compounds for AD used
behavioral endpoints in rodent models as the primary screen owing
to a falsely perceived ease of conducting these experiments and rela-
tive high throughput.8 Moreover, the rodent models used did not nec-
essarily have construct validity for AD, and experiments often evalu-
ated the ability of a test compound to reverse anacutepharmacological
deficit (eg, scopolamine-induced memory deficit) in wild-type or nor-
mal animals, and frequently only inmales. Other screens evaluated the
ability of the test compound to normalize a behavioral phenotype, and
these studies rarely used biomarkers or other clinically translational
endpoints. Young or naïve wild-type animals were often used in place
of aging animals, with the rationale that aged animals were costly and
would minimize throughput. Critically, in many cases pharmacokinetic
(PK) and pharmacodynamic data (PD) in ADmodels at biologically and
pathologically relevant ages have not been evaluated and when per-
formed they were conducted in a single sex without neuropathology.
MODEL-AD is comprehensively addressing many identified con-
cerns. The consortium represents a unique opportunity to standard-
ize practices and provide an established pipeline for preclinical testing
for the AD community while interrogating mechanisms of action that
failed in clinic for AD via a back-translational approach. The Preclini-
cal Testing Core (PTC) has established a streamlined preclinical testing
strategy with go/no-go decision points allowing critical and unbiased
assessments of potential therapeutic agents (Figure 3).
The primary screen includes (1) an initial qualification of the active
pharmaceutical ingredient (API) of the compound to be tested, (2) drug
formulation optimization for dosing in mice, (3) drug stability assess-
ment in that formulation, and (4) multi-dose in vivo pharmacokinet-
ics for the determination of appreciable blood and target tissue activ-
ity in the disease model and at the pathologically and disease-relevant
age in both sexes. Quantification of PK parameters for the parent com-
pound will use standard moment theory (non-compartmental) meth-
ods and parameters.29 Using Cl/F and Vd/F as initial parameter esti-
mates, nonlinearmixed effect analyses30–32 will be performed. Specifi-
cally, tomeet the screening criteria for this go/no-go decision, test arti-
cles need to have low Cl/F, which affords less than or equal to twice
daily dosing, good blood–brain barrier penetration supporting appre-
ciable exposure in brain tissue, appreciable brain retention, and low
serumprotein binding. In the absence of this, compoundswill notmove
forward. Provided the compound meets the “go” criteria, the PK data
(eg, Cmax, Cl/F, Vd/F) will be used to informPK/PDmodeling to develop
the dosing paradigm for the secondary screen where appropriate dis-
ease models at the pathological ages achieves target brain exposure
levels to evaluate disease- (or symptom-) modifying effects.
The secondary screen evaluates target engagement and disease-
modifying activity of the test compound at multiple dose levels, in
both males and females in the disease model at the pathologically rel-
evant age using non-invasive in vivo PET/MRI as a pharmacodynamic
readout of cerebral changes in metabolism (18F-FDG), cerebral blood
flow (64Cu-PTSM), Aβ deposition (18F-AV45), or tau deposition (18F-
AV1451). PET and MRI images will be coregistered,33 and mapped to
stereotactic mouse brain coordinates34 and volume of interest (VOI)
extracted from a mouse brain atlas. Each VOI will be analyzed for
standardized uptake value (SUV) or %ID/g according to published
methods.35 At the completion of the study, blood samples are collected
and processed for plasma to confirm PK from the primary screen. To
permit secondary confirmation for PET and autoradiography studies,
tissue sections will be immunostained with Aβ, tau, or neuroinflamma-
tion antibodies.
Plasma concentrations across animal models and dose levels will
be combined with PET, autoradiography, and secondary confirmation
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F IGURE 3 Workflow for testing compounds through the Preclinical Testing Core. API, active pharmaceutical ingredient; IU, Indiana
University; MRI, magnetic resonance imaging; PET, positron emission tomography; PITT, University of Pittsburgh School ofMedicine; PK,
pharmokinetic; QC, quality control.
data for PK/PD model analysis (ie, direct effect, indirect response, sig-
nal transduction, etc) will be assessed for each compound.36 Only after
demonstrating target engagement will test compounds move to the
tertiary functional assessment.
Tertiary screening will evaluate both dose response curve and
dose range regiments (acute/chronic, route of administration and
pretreatment time) to determine disease-modifying effects of the
test compound to normalize a disease-related functional phenotype.
Tertiary screening will include assessments of cognition (eg, working
memory) and activity measures (eg, locomotor activity, motor coor-
dination) to identify whether the dose range perceived to improve a
functional (ie, memory) deficit is without any side effects that con-
found the interpretation of the data or suggest a limited therapeutic
window. Importantly, the PTC is well aware of the translational limi-
tations of the behavioral assays historically used to predict cognitive
improvement in mouse models (eg, water maze, fear conditioning,
novel object recognition). In this respect it is important to point out
that behavioral outcome measures are limited and only being used
as tertiary screens after target engagement has been confirmed in
the secondary screens, described above. Further, in lieu of a large
battery of behavioral assays for cognitive outcome measures which
have for all intents and purposes failed to translate to the clinic, the
PTC will use improved translational assays such as electroencephalo-
gram as functional outcome measures.45,46 At the conclusion of the
tertiary screen, plasma and brain samples are used to confirm PK
and brain samples are also sent for post-treatment transcriptomics
analysis.
This approach is innovative, first by establishing this standardized,
streamlined preclinical screening strategy, which has been validated,
and provides access to these resources including standard operating
procedures, all raw data along with negative and positive findings, and
hands-on training opportunities to the AD research community.
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5 SCREENING THE OPTIMAL
PHARMACEUTICAL FOR ALZHEIMER’S
DISEASE (STOP-AD)
The PTC supports preclinical screening of test compounds nominated
by the greater research community through its streamlined preclinical
screening strategy in mouse models developed and characterized by
the Disease Modeling Project (DMP). Researchers can apply through
the STOP-AD portal (www.STOPADportal.synapse.org). Compounds
selected for screening will be conductedwithin the PTC labs at Indiana
University and theUniversity of Pittsburgh. Submitters are required to
provide detailed data and information about the compound they wish
to nominate. A review panel consisting of experts in pharmacology,
pharmacokinetics, neuroscience, animal model systems, behavioral
pharmacology, preclinical imaging, genetics, and AD will provide a
composite score based on novelty of science, relevance of target for
AD, chemical properties of the compound including optimal drug-like
properties, and quality of the data available for assessment. Selected
compounds will be best matched to a MODEL-AD mouse model
based on mechanism of action and relevant PD endpoint. Access to
this rigorous testing pipeline is innovative and a major benefit to
researchers that may not otherwise have the resources available
to conduct comprehensive in vivo PK, PD, preclinical imaging, and
functional evaluations of their test compounds. Consequently, the PTC
resources are being leveraged by the NIA’s newly funded Alzheimer’s
Centers for the Discovery of New Medicines (TREAT-AD), which will
facilitate advancing compounds with novel mechanisms of action from
early drug discovery stages to preclinical efficacy testing.
6 SUMMARY AND OUTLOOK
Optimizing the return from the next generation of animal models for
AD will require combining contemporary genetics, computational
biology, and genetic engineering to create a range of models that
faithfully recapitulate the disease. MODEL-AD is configured to fully
exploit contemporary resources to create the next generation of LOAD
models and, moving forward, will be augmented with novel informa-
tion and technologies. The expanded efforts to quantify proteins and
metabolites in addition to transcriptomes by AMP-AD can be readily
reproduced inmousemodels. This will allowmultiscalemolecular com-
parisons between novel models and human LOAD cohorts, possibly
identifying subpopulations of AD patients with distinct neuropathol-
ogy and/or genetic etiology. Such efforts can be greatly enriched with
the integration of functional information from other model systems,
such as induced pluripotent stem cell culture and fly populations.
Furthermore, using inbred genetic models enables a broader study of
how genetic backgrounds alter AD risk factors, both through gene–
gene and gene–environment interactions. The recent proliferation
of genetically complex mouse populations (eg, Diversity Outbred,
Heterogeneous Stock) and inbred lines (eg, Collaborative Cross, BXD)
provide the resources to systematically study how susceptibility to
neurodegeneration varies by strain and, in mapping populations, spe-
cific genetic factors. Alignment of multiscale phenotypes (molecular,
histological, and behavioral) of these models to human data will likely
identify key pathways and processes that drive neuropathology and
LOAD. Of note, while much of LOAD is driven by the interaction
between aging and genetics, there is a considerable influence of
environmental factors, much of which will not be modeled or explored
by this consortium. However, MODEL-AD will provide the next gener-
ation of mouse models to the research community where the impact
of environment, such as diet, stress, social isolation/environmental
enrichment, the microbiome, and other influences can be determined
and subsequently used to develop animalmodels of LOAD in additional
species.
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